- Home
- HOTH vs NLSP Comparison
HOTH vs NLSP Comparison
Compare HOTH & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- NLSP
- Stock Information
- Founded
- HOTH 2017
- NLSP 2015
- Country
- HOTH United States
- NLSP Switzerland
- Employees
- HOTH N/A
- NLSP N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- HOTH Health Care
- NLSP Health Care
- Exchange
- HOTH Nasdaq
- NLSP Nasdaq
- Market Cap
- HOTH 8.3M
- NLSP 5.8M
- IPO Year
- HOTH 2019
- NLSP 2021
- Fundamental
- Price
- HOTH $0.97
- NLSP $1.65
- Analyst Decision
- HOTH Strong Buy
- NLSP
- Analyst Count
- HOTH 3
- NLSP 0
- Target Price
- HOTH $4.00
- NLSP N/A
- AVG Volume (30 Days)
- HOTH 218.1K
- NLSP 104.5K
- Earning Date
- HOTH 05-20-2025
- NLSP 05-19-2025
- Dividend Yield
- HOTH N/A
- NLSP N/A
- EPS Growth
- HOTH N/A
- NLSP N/A
- EPS
- HOTH N/A
- NLSP N/A
- Revenue
- HOTH N/A
- NLSP N/A
- Revenue This Year
- HOTH N/A
- NLSP N/A
- Revenue Next Year
- HOTH N/A
- NLSP N/A
- P/E Ratio
- HOTH N/A
- NLSP N/A
- Revenue Growth
- HOTH N/A
- NLSP N/A
- 52 Week Low
- HOTH $0.58
- NLSP $1.30
- 52 Week High
- HOTH $3.80
- NLSP $18.40
- Technical
- Relative Strength Index (RSI)
- HOTH 59.33
- NLSP 57.79
- Support Level
- HOTH $0.85
- NLSP $1.56
- Resistance Level
- HOTH $0.95
- NLSP $1.78
- Average True Range (ATR)
- HOTH 0.06
- NLSP 0.09
- MACD
- HOTH 0.02
- NLSP 0.03
- Stochastic Oscillator
- HOTH 95.42
- NLSP 67.50
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.